Publications by authors named "Qiu-Mei Deng"
Objectives: De novo mesenchymal-to-epithelial transition (MET) gene fusions in non-small cell lung cancer (NSCLC) are a promising target for MET tyrosine kinase inhibitors (TKIs). We aimed to examine the response to targeted therapy with MET TKIs and resistance mechanisms in de novo MET fusion-positive NSCLC as these have not been comprehensively explored.
Materials And Methods: We examined the MET fusions in 4,429 patients with advanced-stage NSCLC using targeted next-generation sequencing and validated the results using RT-PCR.
Article Synopsis
- Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) shows strong responses to ALK tyrosine kinase inhibitors (TKIs), particularly in cases involving EML4-ALK fusions, but there is limited research on HIP1-ALK fusions.
- A study of 11 patients with HIP1-ALK fusions in Chinese centers reported a high response rate of 90% for crizotinib treatment, with promising survival outcomes although the sample size was small.
- Resistance to ALK-TKIs in these patients is linked to genetic mutations and fusions, indicating the need for larger studies to better understand treatment efficacy and resistance mechanisms in HIP1-ALK-rearranged NSCLC.